Vol. 4 No. 3 (2025)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Khan et al - 2025

Therapies Implications of Cytokines and Vaccines

Fahad Said Khan

Department of Eastern Medicine, Faculty of Medical and Health Sciences, University of Poonch Rawalakot Azad Kashmir Pakistan

Leena Hameed

Faculty of Eastern Medicine, Hamdard University Karachi Pakistan

Muhammad Akhlaq

Research department, Hamdard University Karachi, Pakistan

Shamaila Kausar

Department of Microbiology, University of Lahore, Pakistan

Nosheen Naseem

Department of Eastern Medicine, Faculty of Medical and Health Sciences, University of Poonch Rawalakot Azad Kashmir Pakistan

Rabia Anum

Institute of Business Management, Karachi Pakistan

Arsalan Abid

Department of Nursing and Community Health, Faculty of Public Health, Glasgow Caledonian University Glasgow

Rimsha Zainab

Department of Botany, Shaheed Benazir Bhutto Women University, Peshawar, Pakistan

Idrees Khan

University College of Conventional Medicine, The Islamia University of Bahawalpur

Fethi Ahmet Ozdemir

Department of Molecular Biology and Genetics, Faculty of Science and Art, Bingol University, Bingol, 12000, Türkiye

Gawel Solowski

Department of Molecular Biology and Genetics, Faculty of Science and Art, Bingol University, Bingol, 12000, Türkiye

Muhammad Akram*

Department of Eastern Medicine, Government College University Faisalabad Pakistan

Corresponding Author Email: muhammadakram@gcuf.edu.pk

Vol. 4 No. 3 (2025)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Author Details

Keywords: Therapies Implications; Cytokines; Vaccine; Disease Therapeutics; Immunotherapy

Received on 21 July, 2024

Accepted on 23 Aug 2025

Published on 25 Aug 2025

Corresponding E-mails & Authors*:

Muhammad Akram

Abstract

Cytokine-based therapeutics functions by modulating immunological homeostasis within the tumor microenvironment through targeted activation or suppression of immune effectors mechanisms. These regulatory proteins operate through autocrine, paracrine, and endocrine signaling pathways across diverse pathological contexts, including infection, autoimmunity, inflammation, and malignancy, where they coordinate both innate and adaptive immune responses. Understanding the pleiotropic nature of cytokines, their functional redundancy, overlapping biological activities and associated adverse effects is essential for therapeutic development. This review examines the clinical applications of cytokine therapies and their emerging role in vaccine immunology.

INTRODUCTION

Prophylactic interventions represent the most effective strategy for disease prevention, yet antimicrobial resistance has emerged as a significant challenge when pathogen eradication remains incomplete following monotherapy. Particular attention must be directed toward immunocompromised populations, where standard therapeutic approaches may prove inadequate. In these vulnerable groups, vaccine-induced immune responses may be attenuated, necessitating enhanced immunological support.

Cytokines serve as critical mediators of immune function, coordinating antigen presentation and immune memory formation while potentially serving as vaccine adjuvants to overcome resistance mechanisms. This review examines the kinetics and adjuvant properties of cytokines in therapeutic immune modulation and their clinical applications in symptomatic management.

Cytokines constitute a diverse family of immunomodulatory proteins secreted by various cell types, functioning as intercellular communication molecules. These small signaling proteins exhibit both stimulatory and inhibitory properties, requiring careful consideration of their dual nature given potential cytotoxic effects. The cytokine network's complexity presents both opportunities and challenges, with numerous cytokines currently under investigation for immunotherapeutic applications. Interleukin-2, interleukin-15, and interleukin-12 have demonstrated particular promise in clinical trials and represent advancing frontiers in treatment protocols.

Cytokines constitute a diverse family of immunomodulatory proteins secreted by various cell types, functioning as intercellular communication molecules. These small signaling proteins exhibit both stimulatory and inhibitory properties, requiring careful consideration of their dual nature given potential cytotoxic effects. The cytokine network's complexity presents both opportunities and challenges, with numerous cytokines currently under investigation for immunotherapeutic applications.

Contemporary immunotherapy strategies increasingly incorporate cytokine modulation to enhance treatment efficacy. Interleukin-2, interleukin-15, and interleukin-12 have demonstrated particular promise in clinical trials and represent advancing frontiers in treatment protocols (Zhang et al., 2025). Recent evidence suggests that targeted cytokine therapy can restore immune competence in patients with acquired immunodeficiency syndromes and enhance vaccine responsiveness in elderly populations.

The therapeutic window for cytokine interventions remains narrow, with dose-limiting toxicities including cytokine release syndrome and autoimmune complications requiring careful monitoring (Li et al.2025). Emerging approaches focus on localized

delivery systems and engineered cytokine variants with improved safety profiles. Personalized cytokine therapy, guided by individual immune profiling and genetic markers, represents a promising avenue for optimizing therapeutic outcomes while minimizing adverse effects (Belardelli et al., 2002; Parmiani et al., 2000).

THERAPIES IMPLICATIONS OF CYTOKINES

Cytokines function as essential regulators of immune homeostasis, orchestrating complex intercellular communication networks. Multiple cytokine species modulate immune signaling cascades, with interleukin-2 (IL-2) serving as a paradigmatic example of pleiotropic immune regulation (Zhu et al., 2025). IL-2 exhibits broad tissue distribution and multifaceted biological activities, primarily functioning as a T-cell growth factor while simultaneously influencing diverse lymphocyte subpopulations through distinct receptor-mediated signaling pathways. The complexity of IL-2's immunomodulatory effects encompasses both stimulatory and regulatory functions, reflecting the intricate balance required for optimal immune responses. Previous investigations have examined the nomenclature and classification systems for these cellular populations (Fehniger et al., 2002; Waldmann et al., 2006). Given IL-2's diverse physiological effects across multiple cell types in healthy tissue, the mechanisms underlying its neurological impact remain incompletely characterized.

Small molecular weight cytokines, typically under 30 kDa, are primarily composed of glycoprotein structures that facilitate intercellular communication and immune surveillance (Tizard, 1996). These signaling molecules serve as mediators of cellular responses rather than direct antimicrobial agents, coordinating immune functions through cell-to-cell communication networks. Cytokines operate through paracrine and

autocrine mechanisms, functioning as extracellular messengers that maintain immunological equilibrium through complex regulatory circuits.

Upon binding to their cognate receptors on target cells, cytokines initiate intracellular signaling cascades that modulate gene expression and cellular behavior in response to various stimuli (Randall and Goodborn, 2008). The cytokine-receptor interaction system incorporates feedback mechanisms to prevent excessive activation, as dysregulated cytokine expression can lead to pathological inflammatory responses and adverse clinical outcomes. Cytokines function as key mediators in immune system regulation, controlling lymphocyte activation, cellular communication, proliferation patterns, and regenerative processes. These signaling molecules demonstrate multifaceted biological activities, displaying both pro- and anti-inflammatory characteristics that create intricate regulatory cascades. The complexity of these overlapping pathways results in variable cellular responses that are not yet fully elucidated in current research (Tizard, 1996). Cytokines demonstrate diverse functional roles across multiple physiological processes, including modulation of cellular regulation, immune pathway coordination, inflammatory responses, developmental processes, gene expression control, hematopoietic differentiation, and proliferative activity regulation. Additionally, these signaling molecules contribute significantly to tissue repair mechanisms and wound healing processes (Cutler and Brombacher, 2005). The clinical applications of cytokines have been established across numerous therapeutic contexts and experimental models. Research indicates that cytokine-receptor interactions within cellular compartments may facilitate targeted immunotherapeutic interventions aimed at reconstituting immune function (Cutler and Brombacher, 2005). Specific cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF), have

demonstrated both potent biological activity and manageable safety profiles in clinical applications (Dhama et al., 2013a & b).

Cytokines are low-molecular-weight proteins that function as critical signaling mediators in disease pathogenesis and host immune responses. The expression profiles of specific cytokines vary according to pathogenic stimuli, with microbial invasion triggering distinct cytokine cascades that enhance the host's antimicrobial capacity. Major cytokine families, including chemokines, interferons (IFNs), interleukins, and lymphokines, have been extensively characterized in scientific literature over decades.

Current databases document over 7193 distinct cytokine entities with thousands of associated research publications and therapeutic patent (Matin et al., 2025). Among the most extensively studied cytokines are the interferons, which possess potent antiviral properties through inhibition of viral replication mechanisms. The interferon family is categorized into three types based on receptor binding characteristics and structural homology: Type I (including IFN-α and IFN-β subtypes), Type II (IFN-γ), and Type III (IFN-λ). Due to their antiviral efficacy, interferon-based therapeutics has been clinically employed for over two decades, including applications in severe acute respiratory syndrome treatment.

Interleukin-33 represents the newest member of the IL-1 cytokine family, previously designated as IL-1F11. Originally identified as a nuclear factor in endothelial cells, IL-33 was initially characterized through vascular studies in canine models before its broader immunological functions were elucidated (Yanagisawa et al., 1993) IL-33 functions as a nuclear factor within endothelial cells, where it localizes to the cellular nucleus and participates in transcriptional regulation. In 2005, a comprehensive characterization of this protein was achieved through computational analysis, revealing

its structural organization (Peng et al., 2025). Bioinformatics studies identified IL-33's characteristic β-barrel architecture, consisting of 12 β-strand domains that form the typical immunoglobulin-like fold shared with other IL-1 family members and certain growth factors involved in fibroblast development. (Onda et al., 1999). IL-33 functions as a dual-activity alarmin, serving both nuclear and cytokine roles depending on its cellular localization and release mechanisms following tissue damage or cellular stress(Si et al., 1998) Upon extracellular release, IL-33 exerts its cytokine effects through binding to the ST2 receptor (also known as IL-1RL1) in conjunction with the co-receptor IL-1RAcP (interleukin-1 receptor accessory protein). IL-33 expression is widely distributed across diverse cell populations, including endothelial and epithelial cells, vascular smooth muscle cells, keratinocytes, astrocytes, adipocytes, fibroblasts, hepatic stellate cells, and various immune cells such as monocytes, macrophages, and hepatocytes

(Iwahana et al., 2004).Target cells responsive to IL-33 signaling encompass B lymphocytes, Th2 cells, CD8+ T cells, macrophages, dendritic cells, mast cells, basophils, and innate lymphoid cells, which are distributed throughout multiple organ systems including pulmonary, gastrointestinal, hepatic, splenic, and cutaneous tissues (McSorley et al., 2014). Released IL-33 mediates complex signaling networks through autocrine, paracrine, and contact-dependent mechanisms, playing crucial roles in immune activation, tissue homeostasis, and inflammatory pathway regulation (Fu et al., 2016). The IL-33/ST2 signaling cascade operates through cytoplasmic Toll/interleukin-1 receptor (TIR) domain interactions, recruiting adapter molecules including MyD88 and activating downstream serine-threonine kinases such as IRAK1, IRAK4, and TRAF6. This signaling complex subsequently activates key transcription factors including nuclear factor-κB (NF-κB), activator protein-1 (AP-1), and mitogen-activated protein kinase

(MAPK) pathways. Receptor antagonists of IL-33 function by suppressing NF-κB-mediated transcriptional activation under physiological conditions. IL-33 demonstrates significant potential as a mucosal adjuvant, enhancing antibody responses and promoting robust adaptive immunity characterized by durable immunological memory (Hudson et al. 2008).

THERAPIES IMPLICATIONS OF VACCINE

A vaccine consists of immunogenic materials designed to elicit protective antibody responses and confer immunity against specific infectious diseases. These preparations contain either attenuated or inactivated pathogens, pathogen-derived components, or synthetically produced antigenic determinants that stimulate immune recognition without inducing pathological disease states.

RESISTANT RESPONSES AND CYTOKINES

Adaptive immune responses can be categorized into two primary effector pathways: cell-mediated immunity and humoral immunity. The predominant immune response phenotype depends on the cytokine milieu present during initial antigen presentation. Type 1 immune responses, characterized by production of IL-2, IFN-γ, and TNF-β, promote cellular immunity and are associated with enhanced resistance to intracellular pathogens. Conversely, type 2 responses, driven by cytokines including IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13, facilitate antibody-mediated immunity and are particularly effective against extracellular threats (Krajewski et al., 2025). While this paradigm was initially described for CD4+ T helper cells, current understanding recognizes that both CD4+ and CD8+ T cell subsets can differentiate into Type 1 or Type 2 phenotypes based on their cytokine secretion profiles. Naive T cells retain developmental plasticity, with their ultimate effector phenotype determined by the cytokine environment encountered

during activation and differentiation. The balance between these responses is maintained through reciprocal regulation: IFN-γ and IL-12 promote Type 1 cell development while simultaneously suppressing Type 2 responses, whereas IL-4 enhances Type 2 differentiation and inhibits Type 1 cell generation (Gerard et al., 2008).

CYTOKINES AS DISEASE THERAPEUTICS

Cytokine research has revolutionized therapeutic paradigms, fundamentally transforming treatment approaches across multiple clinical domains. Current therapeutic approaches include the use of recombinant or purified cytokines as treatment modalities, alongside the design of selective inhibitors aimed at counteracting harmful cytokine activity. Established cytokine-based therapeutics include hematopoietic growth factors for bone marrow stimulation, localized growth factors for tissue repair, and interferons for antiviral and immunomodulatory applications across diverse clinical conditions Kungwankiattichai, S., & Maziarz, R. T. (2025).. Conversely, cytokine antagonist therapies have demonstrated significant efficacy, particularly anti-TNF agents in the management of inflammatory bowel disease and other chronic inflammatory disorders (Varona and Villamayor, 2007). Cytokines serve as potent immunomodulatory adjuvants that can enhance anti-inflammatory therapeutic regimens. These signaling molecules regulate both the magnitude and phenotype of immune responses, playing critical roles in disease progression and vaccine efficacy. Through precise modulation of cytokine networks, clinicians can potentially optimize therapeutic outcomes and improve immunization strategies. (Villamayor, 2007).

Cytokines orchestrate immune surveillance mechanisms and serve as critical mediators in initiating host defense responses against pathogenic threats. IL-1 acts as a pivotal upstream mediator by inducing IL-2 receptor expression and activating colony-

stimulating factor receptors, thereby driving leukocyte maturation and proliferation (Cheng et al., 2025).

The coordinated expression and therapeutic application of specific interleukins, including IL-2, IL-4, IL-6, and IL-8, represent essential components in maintaining immune homeostasis and regulating inflammatory processes. These cytokines collectively contribute to cellular recruitment, activation, and the sustained maintenance of appropriate immune responses (Kayamuro et al., 2010). The incorporation of recombinant cytokines as vaccine adjuvants offers significant therapeutic advantages by enhancing both the magnitude and quality of antigen-specific immune responses. Cytokines function as potent immunomodulatory agents that can direct the polarization of T helper cell responses, shifting the balance between Th1 and Th2 phenotypes to optimize vaccine-induced immunity. This targeted modulation of cytokine networks enables the development of tailored immune responses that enhance protective efficacy against specific pathogens (Varona and Villamayor, 2007).

In murine models, cytokines including IL-1, IL-2, and interferons are frequently employed to induce acute immune responses for experimental purposes. Veterinary immunology research in ruminant species has demonstrated that ovine and bovine IL-1 and IL-2 homologs exhibit similar immunostimulatory properties Cohen, N., & Haynes, L. (2024). Investigations into cytokine adjuvant effects on bovine viral diarrhea virus (BVDV) vaccination have examined the enhancement of antibody responses targeting the major envelope glycoprotein E2. Evidence suggests that IL-2 and GM-CSF administration augments cellular immune responses and strengthens protective immunity against BVDV, with synergistic benefits observed when combined with standard vaccination approaches

(Varona and Villamayor, 2007). DNA vaccination efficacy can be enhanced through cytokine-mediated modulation of antigen presentation pathways, particularly through optimization of MHC class II-restricted T lymphocyte activation. In avian species, cytokines have demonstrated potential for augmenting DNA vaccine responses against various poultry diseases, including coccidiosis, infectious bronchitis, Newcastle disease, and avian influenza (Bodman-Harris et al., 2024). For pathogen-specific applications, cytokines such as IL-4 and IL-10 have shown promise as molecular adjuvants when co-administered with DNA vaccines or incorporated as genetic components within plasmid constructs, enhancing both humoral and cellular immune responses

(Figueiredo et al., 2010). Cytokines include IFN-type and IFN-; IL-2 and 12 have a role for the training of some potent auxiliaries, i.e., less qualified Freund assistants such as oligodeoxynucleotides and alpine CpG. IFN-α is also an IFN-; IL-2, 12, 15, 18 and 21; In GM-CSF in the fetus with tyrosine kinase (FLT) - link 3 can negatively affect the reaction positively. An important problem in each is that hemi-cytokine recombinant is caused by the binding of liposomes and the synthesis of co-vectors that direct antibodies to DNA (Tovey and Lallemand, 2010).

IL-1 demonstrates adjuvant properties that enhance immune recognition of poorly immunogenic antigens, including tumor-associated antigens. However, the pro-inflammatory nature of IL-1 presents significant clinical challenges due to systemic toxicity concerns Jones, O. Y. (2024). The IL-1 receptor antagonist (IL-1Ra) represents a naturally occurring competitive inhibitor that lacks the inflammatory properties of IL-1β, offering therapeutic potential with reduced adverse effects. Selective IL-1β inhibition can be effectively utilized in immunotherapeutic contexts, particularly in applications requiring enhanced T cell activation and antigen presentation without excessive

inflammatory responses. This approach enables the identification and targeting of genes involved in T cell-antigen interactions while maintaining controlled inflammatory environments conducive to therapeutic immune responses (Kayamuro et al. 2010).

Given the need for novel therapeutic agents against diverse pathogens, cytokines are increasingly being evaluated as vaccine adjuvants. IL-12, a key Th1-polarizing cytokine, activates natural killer (NK) cells and promotes T and B lymphocyte responses, leading to IFN-γ production and Th1 cell differentiation (Ji et al., 2025). As an immunostimulatory agent, IL-12 enhances antibody production through multiple mechanisms. Experimental approaches utilizing dual plasmid systems co-expressing IL-2 demonstrate enhanced immunogenicity. Murine studies employing IL-2 co-delivery showed significant modulation of antibody isotype responses against HIV antigens, with notable shifts from IgG1 to IgG2a production, indicating enhanced Th1-biased immunity. Separate investigations examining IL-2 expression in *Lactococcus lactis* delivery systems revealed substantial increases in serum IgG levels following immunization protocols. Additionally, studies incorporating IL-15 into DNA vaccination strategies targeting herpes simplex virus glycoprotein B have demonstrated the cytokine's potential as an effective immunomodulatory adjuvant (Toka and Rouse, 2005). Intranasal administration of interferons combined with influenza antigens has demonstrated enhanced mucosal immunity and improved vaccine efficacy. Cancer immunotherapies encompass diverse treatment modalities designed to overcome tumor-induced immunosuppression through various mechanistic approaches. These include the use of tumor cell lysates, synthetic peptides, monoclonal antibodies, DNA vaccines, and antigen-presenting cell-based therapies, either as monotherapy or in combination protocols. Traditional cancer treatments, including surgery, chemotherapy, and radiotherapy, have shown variable

success rates (Sordo-Bahamonde et al., 2023), with newer immunotherapeutic approaches demonstrating significant promise. Cytokines function as potent immunological adjuvants that enhance antitumor immunity by promoting inflammatory cell recruitment, augmenting cytotoxic activity, and stimulating effector cell proliferation. Clinical evidence demonstrates that cytokine incorporation into cancer vaccines can restore immune surveillance through enhanced T cell and antigen-presenting cell trafficking to lymphoid tissues and tumor microenvironments. Specific cytokine families, particularly the common gamma-chain cytokines including IL-2, IL-7, IL-15, and IL-21, utilize shared signaling pathways to activate T lymphocytes and natural killer cells, playing crucial roles in antitumor immune responses. Sickle cell disease represents a chronic inflammatory condition characterized by elevated pro-inflammatory cytokine expression. Clinical studies demonstrate significantly increased levels of IL-6, IL-4, and IFN-γ in patients with sickle cell disease compared to healthy controls. Additionally, anti-inflammatory cytokines including IL-10 and TGF-β are paradoxically elevated, which may contribute to immunosuppression. This is clinically relevant as IL-10 can suppress CD8+ T cell responses during respiratory infections, potentially increasing morbidity and pulmonary complications in affected patients. Delayed immune responses to pneumococcal infections in sickle cell disease patients, with impaired clearance extending beyond typical recovery periods, underscore the urgent need for enhanced vaccination strategies in this vulnerable population (Coomer et al., 2025). Furthermore, the interactions between hydroxyurea or computed tomography findings and antibiotic therapy remain unclear (Upadhyay et al. (2025). Sameh et al. (2015) reported reduced immune protection against influenza A (H1N1) pdm09 infection in individuals with sickle cell anemiaCytokines function as essential immunomodulatory mediators that serve as

adjuvants in disease management and therapeutic interventions. The comprehensive understanding of key cytokine networks is increasingly recognized as fundamental to optimal immune system function. While various immunostimulatory cytokines have been evaluated as therapeutic adjuvants, IL-12 demonstrates superior efficacy compared to alternative cytokine-based approaches. Research has established IL-12's enhanced therapeutic potential relative to other immunostimulatory cytokines, including IL-2 and IL-15, particularly in promoting robust T cell activation and proliferation (Xu et al., 2024). Furthermore, despite potential adverse effects, cytokine-based therapies can overcome treatment resistance by counteracting immunosuppressive mediators such as IL-10 and TGF-β, which normally inhibit effector T cell function and promote regulatory T cell (Treg) expansion while impairing dendritic cell maturation. Consequently, the strategic selection of appropriate cytokine adjuvants is crucial for overcoming tumor immune evasion mechanisms (Chen et al., 2013).

Contemporary cancer immunotherapy research over the past decade has identified two principal therapeutic strategies. First, optimal antigen selection and delivery systems can enhance DNA vaccination efficacy and stimulate protective immune responses, addressing challenges related to antigen processing, tumor heterogeneity, and immune escape. Second, combination approaches incorporate immunomodulatory interventions designed to prevent malignant cell infiltration and neutralize immunosuppressive cytokine production, thereby reversing immunosuppression within the tumor microenvironment.

CYTOKINES/ADJUVANTS

Cytokines demonstrate the capacity to activate receptor-bearing T lymphocytes within immune response cascades. These molecules are typically co-administered with antigens,

either as recombinant proteins combined with plasmid vectors or monoclonal antibodies. Frequently utilized cytokines in current clinical investigations include IL-2, IL-12, and GM-CSF. IL-2 regulates T cell differentiation, balancing regulatory T cell (Treg) development with effector T cell activation. Its therapeutic efficacy against metastatic melanoma and renal cell carcinoma has received FDA approval (McDermott et al., 2004). IL-12 represents another critical cytokine that enhances T cell functionality and promotes antibody production when combined with immunomodulatory agents (Gupta et al. 2015). Plasmid-based IL-12 delivery systems targeting cervical malignancies have demonstrated enhanced immunity with concurrent reduction of myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment. GM-CSF contributes to various therapeutic applications through its role in dendritic cell maturation and T cell proliferation, though this molecule may also promote MDSC formation, illustrating the complex dual functions of cytokines in vivo. Contemporary therapeutic strategies can address diverse pathological conditions, utilizing established knowledge from SARS and MERS treatment protocols to inform rational approaches for SARS-CoV-2 interventions. Patent analysis reveals four primary therapeutic categories: antiviral compounds, cytokine modulators, immunotherapeutic interventions, and RNA-based detection methods, alongside vaccines for SARS-related diseases. Among 500 treatment and prevention patents, antiviral inhibitors constitute the largest category (363), followed by immunomodulatory systems (99), RNA-binding factors (35), and cytokines (22).

Dendritic cells function as professional antigen-presenting cells that effectively prime B and T lymphocytes while producing cytokines that drive cytotoxic T lymphocyte clonal expansion (Banchero et al., 1998). Given their capacity to generate broad-spectrum immune responses, DC-based therapeutics has gained significant research

momentum, with clinical trials demonstrating variable but promising efficacy in metastatic disease management (Anguili et al., 2014).

Clinical investigations indicate that IL-8 combined with IL-12p40 demonstrates enhanced therapeutic responsiveness compared to individual cytokine administration. Anti-inflammatory cytokines, including IL-8, can suppress tumor progression through direct effects or modulation of inflammatory cell infiltration. The synergistic relationship between IL-8 and IL-12p40 suggests that combination cytokine therapy may be superior to monotherapy approaches for improving clinical outcomes.

For DC-based therapies to achieve clinical efficacy, they must promote measurable therapeutic responses. Analysis of cytokine profiles within the tumor microenvironment reveals that IL-12p40 correlates with treatment durability and response rates. IL-12p40 forms heterodimeric IL-12p70, which stimulates inflammatory cell activation and T cell differentiation toward antitumor phenotypes (Dale et al., 2007). IL-33 demonstrates complex immunomodulatory properties in cancer contexts (Trinchieri et al., 1998); The cytokine can suppress antitumor responses by enhancing cytotoxic T lymphocyte activity, natural killer cell function, and interferon production in melanoma and lung carcinoma models. In cardiovascular contexts, IL-33 exhibits protective effects against atherosclerotic progression through modulation of Th2 responses (Byrne et al., 2011) he cytokine's anti-inflammatory properties involve regulation of IL-4, inflammatory mediators, and IFN-γ production (Liang et al., 201)). In hepatic pathology, the IL-33/ST2 signaling pathway exhibits significant hepatoprotective properties. During lymphocytic choriomeningitis virus (LCMV)-induced acute hepatitis, IL-33 confers liver protection through enhanced recruitment of IFN-γ-producing T cells and natural killer cells, which augment antiviral immune responses and limit viral

replication-mediated hepatocyte, damage (Villareal et al., 2015). In adenoviral hepatitis models, IL-33 administration reduces hepatocellular injury markers, including decreased alanine aminotransferase (ALT) levels, diminished inflammatory cell infiltration, and increased regulatory T cell populations within hepatic and lymphoid compartments (Liang et al.2015). The protective mechanisms of IL-33 in hepatic ischemia-reperfusion injury involve modulation of liver enzyme levels, specifically aspartate aminotransferase (AST) and ALT, while reducing inflammatory cell recruitment and regulating Th2 responses through NF-κB and MAPK pathway modulation(Lee et al., 2012). In concanavalin A-induced hepatitis models, IL-33 treatment significantly reduces AST and ALT elevations, suppresses Th1 cytokine production, and promotes expansion of regulatory T cells and IL-4-producing CD4+ T cells, thereby limiting hepatic inflammation and tissue damage (Volarevic et al., 2012). L-33 demonstrates broad antimicrobial properties, enhancing host defense mechanisms against various infectious pathogens. In methicillin-resistant Staphylococcus aureus skin infections, IL-33 promotes tissue repair through enhanced cellular proliferation, accelerated wound healing, and optimized neutrophil recruitment to infection sites (Yin et al., 201). Similarly, IL-33 treatment improves outcomes in *Pseudomonas aeruginosa* infections by enhancing macrophage activation and Th2 immune responses (Nickerson et al., 2024). In *Candida albicans* infections, IL-33 augments antimicrobial efficacy through reactive oxygen species pathway activation and improved respiratory tract clearance mechanisms. (Le et al., 2012).

In gastrointestinal pathology, IL-33 demonstrates complex immunomodulatory effects. During Coxsackie B virus-induced pancreatitis, IL-33 promotes pancreatic inflammation

through enhanced production of inflammatory mediators, including IL-4, TNF-α, and IFN-γ, while simultaneously activating cytotoxic CD8+ T cell responses.

Experimental colitis models have revealed that IL-33 administration or blockade confers protection against severe inflammatory disease and associated cognitive impairment (Grobeta et al., 2012). The protective mechanism involves shifting from Th1-mediated inflammatory responses toward Th2-dominated immunity, promoting regulatory T cell expansion and reducing myeloperoxidase activity. IL-33 provides protective immunity against helminthes infections, particularly facilitating *Trichuris muris* expulsion through Th2-mediated effector mechanisms (Yousefi et al., 2021). In neurological contexts, IL-33 demonstrates neuroprotective properties following traumatic brain injury or cerebrovascular accidents by suppressing Th17-mediated inflammation. Evidence from clinical studies suggests that IL-33 may contribute to host defense against influenza infection, although its precise role in allergen-associated airway inflammation remains uncertain and requires further clarification. Current evidence indicates IL-33 influences both protective and pathological immune responses depending on the specific disease context and inflammatory milieu (Kayamuro et al., 2010).

Clinical investigations have demonstrated that IL-33 and its receptor antagonists enhance immune function across multiple pathological conditions, primarily through modulation of innate and adaptive immune responses. IL-33 displays multifaceted immunoregulatory functions, enhancing CD8+ T-cell cytotoxicity, sustaining regulatory T-cell activity, and activating myeloid populations (Kumagai et al., 2024). It exerts anti-inflammatory effects via neutrophil and macrophage modulation, while orchestrating both humoral and cellular immune responses. IL-33 suppresses pro-inflammatory

mediator production from various cell types following tissue injury and regulates NF-κB signaling to limit inflammatory damage. However, in allergic and atopic disorders, IL-33 antagonists demonstrate therapeutic benefit by reducing IgE production, eosinophil recruitment, and Th2-mediated responses. Among immunostimulatory cytokines investigated for cancer immunotherapy, IL-12 demonstrates superior antitumor efficacy when administered in combination treatment protocols

(Chiang et al., 2011). Comparative studies evaluating IL-12 against IL-2 and IL-15 indicate enhanced therapeutic potential in tumor cell elimination strategies. Advances in cancer immunotherapy have significantly improved treatment outcomes for patients with advanced malignancies. While cellular therapies have established efficacy against hematological cancers, effective immune system activation requires appropriate cytokine adjuvants. IL-12 and GM-CSF represent promising cytokines for adoptive cell therapy applications. Research indicates these mediators possess potent antitumor properties and participate in diverse immune mechanisms, including enhancement of antigen presentation and T cell priming. IL-12 promotes activation of multiple effector populations, including T cells, NK cells, and NKT cells, which serve as primary antitumor effectors (Jiang et al., 2024). Furthermore, combination strategies utilizing IL-12 with additional immunomodulatory agents demonstrate synergistic therapeutic effects for advanced cancer treatment. Although IL-12 monotherapy shows antitumor activity, safety considerations have emerged regarding optimal dosing strategies, necessitating combination approaches with GM-CSF to improve therapeutic indices. Additional research is required to optimize combined IL-12 and GM-CSF protocols for enhanced antitumor efficacy.

HIV-1 demonstrates complex interactions with cytokine networks, functioning as either an inhibitor or stimulator of immune responses depending on viral replication status and cellular context. These interactions influence viral transmission and replication both in vivo and in vitro through distinct mechanistic pathways. The virus modulates cytokine production from infected cells, creating immunosuppressive environments. This analysis examines the relationship between cytokines and HIV-1 pathogenesis, identifying mechanisms through which cytokines influence disease progression and highlighting therapeutic applications of cytokine modulation in highly active antiretroviral therapy (HAART) and vaccine development strategies.

CONFINEMENTS OF CYTOKINE USE

Clinical implementation of cytokine therapeutics presents numerous challenges that contemporary physicians must address in both preventive and therapeutic contexts. Maintaining sustained therapeutic efficacy over extended treatment periods remains a significant obstacle in cytokine-based interventions. Achieving optimal bioavailability while preserving cytokine biological activity introduces additional complexity to therapeutic protocols. The inherently short plasma half-life of most cytokines necessitates frequent dosing regimens, which can exacerbate treatment-related adverse effects and compromise patient compliance. Cytokine therapies are associated with diverse toxicity profiles that can produce serious systemic complications (Perera et al., 2025). Frequent adverse effects include pyrexia, rigors, thrombocytopenia, dyspnoea, and cardiovascular events. IL-2 therapy is particularly notable for a unique profile of dose-limiting toxicities, most prominently capillary leak syndrome and cardiac dysfunction, necessitating vigilant monitoring and supportive care

CONCLUSION

Cytokine-based therapeutics represents a promising treatment modality with significant clinical potential. These signaling molecules function as essential mediators of intercellular communication, orchestrating inflammatory responses and immune activation pathways that are fundamental to various therapeutic interventions in human medicine. The development of recombinant cytokines for clinical application presents considerable challenges, as their therapeutic efficacy depends on multiple pharmacokinetic parameters including plasma half-life, tissue distribution, bioavailability, and potential interactions with endogenous cytokine networks in physiological conditions. A primary limitation of cytokine therapeutics is their rapid in vivo clearance and associated dose-limiting toxicities. Polyethylene glycol conjugation (PEGylation) of cytokines has emerged as an effective strategy to extend circulating half-life, thereby reducing dosing frequency requirements while minimizing adverse effects. Given the diverse clinical applications and complex mechanistic properties of cytokine therapeutics, comprehensive understanding of their pharmacological profiles and optimal dosing strategies remains essential for successful clinical implementation

REFERENCES

Anguille, S., Smits, E.L., Lion, E., van Tendeloo, V.F. Berneman, Z.N., (2014). Clinical use of dendritic cells for cancer therapy. The lancet oncology, 15(7), pp.e257-e267.

Banchereau, J. and Steinman, R.M., (1998). Dendritic cells and the control of immunity. Nature, 392(6673), pp.245-252.

Belardelli, F. and Ferrantini, M., (2002). Cytokines as a link between innate and adaptive antitumor immunity. Trends in immunology, 23(4), pp.201-208.

Bodman-Harris, O., Rollier, C. S., & Iqbal, M. (2024). Approaches to enhance the potency of vaccines in chickens. *Vaccines*, *12*(12), 1337.

Byrne, W. L., Mills, K. H., Lederer, J. A., & O'Sullivan, G. C. (2011). Targeting regulatory T cells in cancer. *Cancer research*, *71*(22), 6915-6920.

Chen, L., Zhou, S., Qin, J., Hu, H., Ma, H., et al.(2013). A combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. Molecular Cancer, 12(1), p.153.

Cheng, F., Wang, Y., Gao, Y., Zhang, C., Zhang, Q., Chen, J., ... & Sun, X. (2025). Current Understanding of Epithelial-Derived Alarmins in Chronic Rhinosinusitis with Nasal Polyps. *Clinical Reviews in Allergy & Immunology*, *68*(1), 59.

Chiang, C.L., Maier, D.A., Kandalaft, L.E., Brennan, A.L., Lanitis, E., et al. (2011). Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of translational medicine, 9(1), p.198.

Cohen, N., & Haynes, L. (2024). The phylogenetic conservation of cytokines. In *Phylogenesis of immune functions* (pp. 241-268). CRC Press.

Coomer, C. A., Levin, R. A., & Neri, C. M. (2025). Death from S. pneumoniae in HbSC Disease: Was Expanded Pneumococcal Vaccination Too Late?. *Hemoglobin*, 1-5.

Cutler, A. and Brombacher, F. (2005). Cytokine therapy. Annals of the New York Academy of Sciences, 1056, Natural Products and Molecular Therapy, pp: 16-29.

Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M.T., Wesa, A., et al. (2007). Interleukin-12: biological properties and clinical application. Clinical Cancer Research, 13(16), pp.4677-4685.

Dhama, K., Chakraborty, S., Wani, M.Y., Verma, A.K., Deb, R., et al. (2013). Novel and emerging therapies safeguarding the health of humans and their companion animals: a review. Pakistan journal of biological sciences: PJBS, 16(3), p.101.

Dhama, K., Latheef, S.K., Samad, H.A., Chakraborty, S., Tiwari, R., et al. (2013). Tumor necrosis factor as a mediator of inflammatory diseases and its therapeutic targeting: a review. Journal of Medical Sciences, 13(4), pp.226-235.

Fehniger, T.A., Cooper, M.A. Caligiuri, M.A., (2002). Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & growth factor reviews, 13(2), pp.169-183.

Fernández-Varón, E. and Villamayor, L., (2007). Granulocyte and granulocyte-macrophage colony-stimulating factors as therapy in human and veterinary medicine. The Veterinary Journal, 174(1), pp.33-41.

Figueiredo, C.A., Barreto, M.L., Rodrigues, L.C., Cooper, P.J., Silva, N.B., et al. (2010). Chronic intestinal helminth infections are associated with immune hyporesponsiveness and induction of a regulatory network. Infection and immunity, 78(7), pp.3160-3167.

Fu, Amy KY, Kwok-Wang Hung, Michael YF Yuen, Xiaopu Zhou, Deejay SY Mak, et al. (2016). "IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline." Proceedings of the National Academy of Sciences 113, no. 19: E2705-E2713.

Galvin, K.C., Dyck, L., Marshall, N.A., Stefanska, A.M., Walsh, K.P., et al. (2013). Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumors by suppressing the induction of regulatory T cells. Cancer Immunology, Immunotherapy, 62(7), pp.1273-1282.

Groβ, P., Doser, K., Falk, W., Obermeier, F. and Hofmann, C., (2012). IL-33 attenuates the development and perpetuation of chronic intestinal inflammation. Inflammatory bowel diseases, 18(10), pp.1900-1909.

Gupta, S., Termini, J.M., Rivas, Y., Otero, M., Raffa, F.N., et al. (2015). A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine, 33(38), pp.4798-4806.

Hudson, C.A., Christophi, G.P., Gruber, R.C., Wilmore, J.R., Lawrence, D.A. Massa, P.T., (2008). Induction of IL-33 expression and activity in central nervous system glia. Journal of leukocyte biology, 84(3), pp.631-643.

Iwahana, H., Hayakawa, M., Kuroiwa, K., Tago, K., Yanagisawa, K., et al. (2004). Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1681(1), pp.1-14.

Ji, Y., Xiao, C., Fan, T., Deng, Z., Wang, D., Cai, W., ... & He, J. (2025). The epigenetic hallmarks of immune cells in cancer. *Molecular Cancer*, *24*(1), 66.

Jiang, P., Jing, S., Sheng, G., & Jia, F. (2024). The basic biology of NK cells and its application in tumor immunotherapy. *Frontiers in Immunology*, *15*, 1420205.

Jones, O. Y. (2024). Single Center-Based Real-World Experience on Anti-IL 1 Biological Response Modifiers: A Case Series and Literature Review. *Children*, *11*(9), 1146.

Kaiko, G.E., Horvat, J.C., Beagley, K.W., and Hansbro, P.M., (2008). Immunological decision-making: how does the immune system decide to mount a helper T-cell response?. Immunology, 123(3), pp.326-338.

Kayamuro, H., Yoshioka, Y., Abe, Y., Arita, S., Katayama, K., et al. (2010). Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. Journal of virology, 84(24), pp.12703-12712.

Kayamuro, H., Yoshioka, Y., Abe, Y., Arita, S., Katayama, K., et al. (2010). Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. Journal of virology, 84(24), pp.12703-12712.

Krajewski, D., Ranjitkar, S., Jordan, N., Schneider, S. S., & Mathias, C. B. (2025). IL-33 signaling is dispensable for the IL-10-induced enhancement of mast cell responses during food allergy. *Frontiers in Immunology*, *16*, 1526498.

Kumagai, S., Itahashi, K., & Nishikawa, H. (2024). Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. *Nature Reviews Clinical Oncology*, *21*(5), 337-353.

Kungwankiattichai, S., & Maziarz, R. T. (2025). The history of cytokines and growth factors development. *Best Practice & Research Clinical Haematology*, 101612

Le, H.T., Tran, V.G., Kim, W., Kim, J., Cho, H.R. Kwon, B., (2012). IL-33 priming regulates multiple steps of the neutrophil-mediated anti-Candida Albicans response by modulating TLR and dectin-1 signals. The Journal of Immunology, 189(1), pp.287-295.

Li, S., Zhu, F.X., Zhang, H.B., Li, H. and An, Y.Z., (2013). Pretreatment with interleukin-33 reduces warm hepatic ischemia/reperfusion injury in mice. Chinese Medical Journal, 126(10), pp.1855-1859.

Li, Y. R., Zhu, Y., Chen, Y., & Yang, L. (2025). The clinical landscape of CAR-engineered unconventional T cells. Trends in Cancer.

Liang, Y., Jie, Z., Hou, L., Yi, P., Wang, W., et al. (2015). IL-33 promotes innate IFN-γ production and modulates dendritic cell response in LCMV-induced hepatitis in mice. European journal of immunology, 45(11), pp.3052-3063.

Matin, M., Kapoor, B., Gulati, M., Mickael, M. E., Matin, F. B., Kamińska, A., ... & Atanasov, A. G. (2025). Exploring the innovation landscape of ginger: Insights from patent documentation analysis. *Current Research in Biotechnology*, 100299.

McDermott, D.F., Regan, M.M., Clark, J.I., Flaherty, L.E., Weiss, G.R., et al. (2004). Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of clinical oncology, 23(1), pp.133-141.

McSorley, H.J., Blair, N.F., Smith, K.A., McKenzie, A.N. Maizels, R.M., (2014). Blockade of IL-33 release and suppression of type 2 innate lymphoid cell responses by helminth secreted products in airway allergy. Mucosal immunology, 7(5), pp.1068-1078.

Miller, A.M., Xu, D., Asquith, D.L., Denby, L., Li, Y., et al. (2008). IL-33 reduces the development of atherosclerosis. The Journal of experimental medicine, 205(2), pp.339-346.

Nickerson, R., Thornton, C. S., Johnston, B., Lee, A. H., & Cheng, Z. (2024). Pseudomonas aeruginosa in chronic lung disease: untangling the dysregulated host immune response. *Frontiers in immunology*, *15*, 1405376.

Onda, H., Kasuya, H., Takakura, K., Hori, T., Imaizumi, T.A., et al. (1999). Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. Journal of Cerebral Blood Flow & Metabolism, 19(11), pp.1279-1288.

Parmiani G, Rivoltini L, Andreola G, Carrabba M. (2000). Cytokines in cancer therapy. Immunology letters.74(1):41-4.

Peng, J., Chang, Z., Wang, J., Liao, Z., Yang, Y., Mu, L., ... & Hu, M. (2025). Aerobic exercise ameliorates atherosclerosis-induced cognitive impairment via hippocampal IL-33/NF-κB signaling modulation. *Frontiers in Physiology*, *16*, 1608268.

Perera, A., Chugh, N., & Garcia-Bournissen, F. (2025). Systematic Review of Adverse Events of IL-1 and IL-6 Inhibitor Use in Pediatrics. *The Journal of Pediatric Pharmacology and Therapeutics*, *30*(2), 152-169.

Randall, R.E. and Goodbourn, S., 2008. Interferons and viruses: an interplay between induction, signaling, antiviral responses, and virus countermeasures. Journal of general virology, 89(1), pp.1-47.

Sakai, N., Van Sweringen, H.L., Quillin, R.C., Schuster, R., Blanchard, J., et al. (2012). Interleukin-33 Is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology, 56(4), pp.1468-1478.

Sameh Anwar Hussein Farrag, M. (2015). Molecular pathology of selected porphyria with skin manifestation.

Sarray, S., Saleh, L.R., Saldanha, F.L., Al-Habboubi, H.H., Mahdi, N. Almawi, W.Y., (2015). Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during a vaso-occlusive crisis and steady-state condition. Cytokine, 72(1), pp.43-47.

Sordo-Bahamonde, C., Lorenzo-Herrero, S., Gonzalez-Rodriguez, A. P., Martínez-Pérez, A., Rodrigo, J. P., García-Pedrero, J. M., & Gonzalez, S. (2023). Chemo-immunotherapy: a new trend in cancer treatment. *Cancers*, *15*(11), 2912

Tizard, I.R., (1996). Cytokines and the immune system. Veterinary Immunology: an introduction, 5th ed. WB Saunders Company, Philadelphia, Pa, pp.141-152.

Toka, F.N. and Rouse, B.T., (2005). Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity. Journal of leukocyte biology, 78(1), pp.178-186.

Tominaga, S.I., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K. Komatsu, N., (1999). Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochemical and biophysical research communications, 264(1), pp.14-18.

Tovey, M.G. and Lallemand, C., (2010). Adjuvant activity of cytokines. In Vaccine adjuvants (pp. 287-309). Humana Press, Totowa, NJ.

Trinchieri, G., (1998). Interleukin-12: a cytokine at the interface of inflammation and immunity. In Advances in immunology (Vol. 70, pp. 83-243). Academic Press.

Upadhyay, A., Jha, H. C., Pal, D., & Kumar, A. (2025). Repurposing antibiotics: A dual-action approach against bacteria-induced cancer. *Cancer Pathogenesis and Therapy*, *3*, E01-E11.

Villarreal, D.O., Svoronos, N., Wise, M.C., Shedlock, D.J., Morrow, M.P., et al. (2015). Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. Vaccine, 33(35), pp.4313-4320.

Volarevic, V., Mitrovic, M., Milovanovic, M., Zelen, I., Nikolic, I., Mitrovic, S., Pejnovic, N., Arsenijevic, N. and Lukic, M.L., 2012. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. Journal of hepatology, 56(1), pp.26-33.

Waldmann, T.A., 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Reviews Immunology, 6(8), pp.595-601.

Xu, S., Xu, Y., Solek, N. C., Chen, J., Gong, F., Varley, A. J., ... & Li, B. (2024). Tumor-tailored ionizable lipid nanoparticles facilitate IL-12 circular RNA delivery for enhanced lung cancer immunotherapy. *Advanced materials*, *36*(29), 2400307.

Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T. Tominaga, S.I., (1993). Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Letters, 318(1), pp.83-87.

Yin, H., Li, X., Hu, S., Liu, T., Yuan, B., et al. (2013). IL-33 promotes Staphylococcus aureus-infected wound healing in mice. International immunopharmacology, 17(2), pp.432-438.

Yousefi, Y., Haq, S., Banskota, S., Kwon, Y. H., & Khan, W. I. (2021). Trichuris muris model: role in understanding intestinal immune response, inflammation and host defense. *Pathogens*, *10*(8), 925.

Zhang, T., Ren, C., Yang, Z., Zhang, N., & Tang, H. (2025). Exploration of the role of immune cells and cell therapy in hepatocellular carcinoma. *Frontiers in Immunology*, *16*, 1569150.

Zhu, Y., Lu, Z., Wang, Z., Liu, J., & Ning, K. (2025). Based on the immune system: the role of the IL-2 family in pancreatic disease. *Frontiers in Immunology*, *16*, 1480496.